524 related articles for article (PubMed ID: 33160106)
21. New sonographic marker of borderline ovarian tumor: microcystic pattern of papillae and solid components.
Timor-Tritsch IE; Foley CE; Brandon C; Yoon E; Ciaffarrano J; Monteagudo A; Mittal K; Boyd L
Ultrasound Obstet Gynecol; 2019 Sep; 54(3):395-402. PubMed ID: 30950132
[TBL] [Abstract][Full Text] [Related]
22. Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Long text of the Joint French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa. Part 1: Diagnostic exploration and staging, surgery, perioperative care, and pathology.
Lavoue V; Huchon C; Akladios C; Alfonsi P; Bakrin N; Ballester M; Bendifallah S; Bolze PA; Bonnet F; Bourgin C; Chabbert-Buffet N; Collinet P; Courbiere B; De la Motte Rouge T; Devouassoux-Shisheboran M; Falandry C; Ferron G; Fournier L; Gladieff L; Golfier F; Gouy S; Guyon F; Lambaudie E; Leary A; Lecuru F; Lefrere-Belda MA; Leblanc E; Lemoine A; Narducci F; Ouldamer L; Pautier P; Planchamp F; Pouget N; Ray-Coquard I; Rousset-Jablonski C; Senechal-Davin C; Touboul C; Thomassin-Naggara I; Uzan C; You B; Daraï E
J Gynecol Obstet Hum Reprod; 2019 Jun; 48(6):369-378. PubMed ID: 30936027
[TBL] [Abstract][Full Text] [Related]
23. Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Short text of the French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa.
Lavoue V; Huchon C; Akladios C; Alfonsi P; Bakrin N; Ballester M; Bendifallah S; Bolze PA; Bonnet F; Bourgin C; Chabbert-Buffet N; Collinet P; Courbiere B; De la Motte Rouge T; Devouassoux-Shisheboran M; Falandry C; Ferron G; Fournier L; Gladieff L; Golfier F; Gouy S; Guyon F; Lambaudie E; Leary A; Lecuru F; Lefrere-Belda MA; Leblanc E; Lemoine A; Narducci F; Ouldamer L; Pautier P; Planchamp F; Pouget N; Ray-Coquard I; Rousset-Jablonski C; Senechal-Davin C; Touboul C; Thomassin-Naggara I; Uzan C; You B; Daraï E
Eur J Obstet Gynecol Reprod Biol; 2019 May; 236():214-223. PubMed ID: 30905627
[TBL] [Abstract][Full Text] [Related]
24. [MRI and CT-scan in presumed benign ovarian tumors].
Thomassin-Naggara I; Bazot M
J Gynecol Obstet Biol Reprod (Paris); 2013 Dec; 42(8):744-51. PubMed ID: 24210236
[TBL] [Abstract][Full Text] [Related]
25. Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) - a study of the TOC Consortium.
Braicu EI; Van Gorp T; Nassir M; Richter R; Chekerov R; Gasimli K; Timmerman D; Vergote I; Sehouli J
J Ovarian Res; 2014; 7():49. PubMed ID: 24872845
[TBL] [Abstract][Full Text] [Related]
26. [Diagnostic value of imaging (ultrasonography, doppler, CT, MR, PET-CT) for the diagnosis of a suspicious ovarian mass and staging of ovarian, tubal or primary peritoneal cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
Thomassin-Naggara I; Daraï E; Lécuru F; Fournier L
Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):123-133. PubMed ID: 30686729
[TBL] [Abstract][Full Text] [Related]
27. [Diagnosis of presumed benign ovarian tumors].
Laculle-Massin C; Collinet P; Faye N
J Gynecol Obstet Biol Reprod (Paris); 2013 Dec; 42(8):760-73. PubMed ID: 24210239
[TBL] [Abstract][Full Text] [Related]
28. [Follow-up of patients treated for an epithelial ovarian cancer, place of hormone replacement therapy and of contraception: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
Sénéchal C; Akladios C; Bendifallah S; Ouldamer L; Lecuru F; Rousset-Jablonski C
Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):250-262. PubMed ID: 30685388
[TBL] [Abstract][Full Text] [Related]
29. Performance of IOTA Simple Rules Risks, ADNEX Model, Subjective Assessment Compared to CA125 and HE4 with ROMA Algorithm in Discriminating between Benign, Borderline and Stage I Malignant Adnexal Lesions.
Czekierdowski A; Stachowicz N; Smolen A; Łoziński T; Guzik P; Kluz T
Diagnostics (Basel); 2023 Feb; 13(5):. PubMed ID: 36900029
[TBL] [Abstract][Full Text] [Related]
30. Borderline ovarian tumors and diagnostic dilemma of intraoperative diagnosis: could preoperative He4 assay and ROMA score assessment increase the frozen section accuracy? A multicenter case-control study.
Gizzo S; Berretta R; Di Gangi S; Guido M; Zanni GC; Franceschetti I; Quaranta M; Plebani M; Nardelli GB; Patrelli TS
Biomed Res Int; 2014; 2014():803598. PubMed ID: 25431767
[TBL] [Abstract][Full Text] [Related]
31. [Recommendations for clinical practice: Presumed benign ovarian tumors--short text].
French College of Gynecologists and Obstetricians
J Gynecol Obstet Biol Reprod (Paris); 2013 Dec; 42(8):856-66. PubMed ID: 24210710
[TBL] [Abstract][Full Text] [Related]
32. Estimating the risk of malignancy of adnexal masses: validation of the ADNEX model in the hands of nonexpert ultrasonographers in a gynaecological oncology centre in China.
He P; Wang JJ; Duan W; Song C; Yang Y; Wu QQ
J Ovarian Res; 2021 Dec; 14(1):169. PubMed ID: 34857005
[TBL] [Abstract][Full Text] [Related]
33. Risk for malignant and borderline ovarian neoplasms following basic preoperative evaluation by ultrasonography, ca125 level and age.
Karadag B; Kocak M; Kayikcioglu F; Ercan F; Dilbaz B; Kose M; Haberal A
Asian Pac J Cancer Prev; 2014; 15(19):8489-93. PubMed ID: 25339052
[TBL] [Abstract][Full Text] [Related]
34. Comparison of tumor markers and clinicopathological features in serous and mucinous borderline ovarian tumors.
Alanbay I; Aktürk E; Coksuer H; Ercan CM; Karaşahin E; Dede M; Yenen MC; Ozan H; Dilek S
Eur J Gynaecol Oncol; 2012; 33(1):25-30. PubMed ID: 22439401
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.
Shappell HW; Riopel MA; Smith Sehdev AE; Ronnett BM; Kurman RJ
Am J Surg Pathol; 2002 Dec; 26(12):1529-41. PubMed ID: 12459620
[TBL] [Abstract][Full Text] [Related]
36. Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk.
Vasconcelos I; de Sousa Mendes M
Eur J Cancer; 2015 Mar; 51(5):620-31. PubMed ID: 25661104
[TBL] [Abstract][Full Text] [Related]
37. Borderline ovarian tumor in pregnancy: can surgery wait? A case series.
Vidal Urbinati AM; Iacobone AD; Di Pace RC; Pino I; Pittelli MR; Guerrieri ME; Preti EP; Franchi D
Arch Gynecol Obstet; 2021 Dec; 304(6):1561-1568. PubMed ID: 33950305
[TBL] [Abstract][Full Text] [Related]
38. Borderline Ovarian Tumors: Fifteen Years' Experience at a Scottish Tertiary Cancer Center.
May J; Skorupskaite K; Congiu M; Ghaoui N; Walker GA; Fegan S; Martin CW; O'Donnell RL
Int J Gynecol Cancer; 2018 Nov; 28(9):1683-1691. PubMed ID: 30365457
[TBL] [Abstract][Full Text] [Related]
39. Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China.
Chen H; Qian L; Jiang M; Du Q; Yuan F; Feng W
Ultrasound Obstet Gynecol; 2019 Dec; 54(6):815-822. PubMed ID: 31152572
[TBL] [Abstract][Full Text] [Related]
40. Evaluating use of IOTA two-step strategy to classify adnexal masses identified in pregnancy: pilot study.
Barcroft J; Pandrich M; Del Forno S; Cooper N; Linton-Reid K; Landolfo C; Timmerman D; Saso S; Bourne T
Ultrasound Obstet Gynecol; 2024 May; ():. PubMed ID: 38787921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
